This study evaluates a new aqueous nasal formulation of ipratropium bromide (Atrovent Nasal Spray 0.03%) in subjects with perennial non-allergic rhinitis in a double-blind, placebo-controlled trial.

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for ...

Drug firm Lupin Ltd on Monday (February 10) said it has received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for ipratropium ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ...

Lupin has received approval from the Food and Drug Administration for ipratropium bromide nasal solution (nasal spray), 0.06%, which is a generic of Boehringer Ingelheim's Atrovent Nasal Spray, 0.06%.

Lupin share price fell nearly 2 percent in the early trade on February 11 despite the company received United States Food and Drug Administration (USFDA) approval for nasal spray. At 09:23am ...

Lupin: Lupin Ltd received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for ipratropium bromide nasal solution (0.03%).

Lupin Receives Approval from U. S. FDA for Ipratropium Bromide Nasal Solution (NASAL Spray), 0.03% ...